These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 22481636)

  • 1. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort.
    Jochmann A; Scherr A; Jochmann DC; Miedinger D; Török SS; Chhajed PN; Tamm M; Leuppi JD
    Swiss Med Wkly; 2012; 142():w13567. PubMed ID: 22481636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
    Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
    Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.
    Ding B; Small M; Holmgren U
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1527-1537. PubMed ID: 28579771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reasons for triple therapy in stable COPD patients in Japanese clinical practice.
    Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice.
    Drivenes E; Ostrem A; Melbye H
    BMC Fam Pract; 2014 Mar; 15():42. PubMed ID: 24597538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guideline for the management of chronic obstructive pulmonary disease--2011 update.
    Abdool-Gaffar MS; Ambaram A; Ainslie GM; Bolliger CT; Feldman C; Geffen L; Irusen EM; Joubert J; Lalloo UG; Mabaso TT; Nyamande K; O'Brien J; Otto W; Raine R; Richards G; Smith C; Stickells D; Venter A; Visser S; Wong M;
    S Afr Med J; 2011 Jan; 101(1 Pt 2):63-73. PubMed ID: 21526617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common lung conditions: chronic obstructive pulmonary disease.
    Delzell JE
    FP Essent; 2013 Jun; 409():23-31. PubMed ID: 23767419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study.
    Gunen H; Yilmaz M; Aktas O; Ergun P; Ortakoylu MG; Demir A; Cetinkaya P; Gurgun A; Otlu M; Cilli A; Yilmaz U; Kokturk N; Candemir I; Yakar HI; Ar I; Konya A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2485-94. PubMed ID: 26622176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.
    Qaseem A; Wilt TJ; Weinberger SE; Hanania NA; Criner G; van der Molen T; Marciniuk DD; Denberg T; Schünemann H; Wedzicha W; MacDonald R; Shekelle P; ; ; ;
    Ann Intern Med; 2011 Aug; 155(3):179-91. PubMed ID: 21810710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.
    Scalone G; Nava S; Ventrella F; Bussoli G; Catapano GA; Pennisi A; Dadduzio F; Schino P; Pela R; Bartezaghi M; Morini P; Porpiglia PA; Muscianisi E;
    Pulm Pharmacol Ther; 2018 Dec; 53():68-77. PubMed ID: 30193866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to a COPD treatment guideline among patients in Hong Kong.
    Chan KP; Ko FW; Chan HS; Wong ML; Mok TY; Choo KL; Hui DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3371-3379. PubMed ID: 29238182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse relationship between nonadherence to original GOLD treatment guidelines and exacerbations of COPD.
    Foda HD; Brehm A; Goldsteen K; Edelman NH
    Int J Chron Obstruct Pulmon Dis; 2017; 12():209-214. PubMed ID: 28123293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.
    Wurst KE; Shukla A; Muellerova H; Davis KJ
    COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS; Landis SH; Wurst K; Le H
    Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of early medication use for COPD: a population-based cohort study.
    Falk J; Dik N; Bugden S
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3101-3108. PubMed ID: 27994449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study.
    Ivanov Y; Nikolaev I; Nemeth I
    Int J Chron Obstruct Pulmon Dis; 2018; 13():653-663. PubMed ID: 29503539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.